AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01500889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GroupII: V-Y advancement flap
Description: GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide.
Study NCT01500889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GroupIII: Tailored LIS with V-Y advancement flap
Description: Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
Study NCT04470726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001
Description: Intradermal/intratumoral
Study NCT04470726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV001 suspension
Description: AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection
Study NCT00443456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
Study NCT01192074 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Preprocedure ultrasound examination of the spine
Study NCT01480648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 144807 Placebo
Description: Placebo that represents BI drug
Study NCT01480648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: single dose (low to high dose)
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A Mylotarg plus DA Versus CPX-351
Description: Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B Vosaroxin and Decitabine
Description: If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm D Small molecule or Not
Description: The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm C DA V FLAG-Ida V DAC
Description: If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm E CPX-351 (200 V 300)
Description: If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
Study NCT00950521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercerebral implantation of Autulogous Stem Cells
Description: 2-8 millions Stem cell per patients plus convention therapy
Study NCT00950521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: convention therapy
Description: antiplatelet
Study NCT03557385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iopamidol
Description: aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~* Rate of 4 mL/sec, volume of 10 cc (left coronary system)~* Rate of 3 mL/sec, volume of 6 cc (right coronary system).
Study NCT02272478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm F DA V IDAC
Description: Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
Study NCT03557385 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: adenosine
Description: FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
Study NCT02298231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care Balance Intervention
Description: Standard balance therapy as performed by a physical therapist
Study NCT02298231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mystic Isle Balance Intervention
Description: Balance therapy using virtual reality
Study NCT02298231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mystic Isle Balance Intervention with Dual Task
Description: Balance therapy using virtual reality and performing cognitive tasks
Study NCT01776411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Study NCT02152800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir hydrocholoride
Study NCT02152800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir hydrocholoride
Study NCT02157610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
Study NCT02677064 — intervention group
Intervention type: OTHER
Intervention: assessments
Description: All laboratory assessments performed on this study represent standard of care at our institution. HLA allele typing is performed by the center's HLA laboratory according to standard typing procedures.
Study NCT03557385 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Navvus® Catheter
Description: the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
Study NCT03557385 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CVi® Contrast Delivery System
Description: The CVi® Contrast Delivery System will be used to deliver the contrast medium
Study NCT04392752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dieting intervention
Description: This study includes four laboratory testing sessions over the 50-week period. Testing sessions will be performed over one week. Time points include testing before the diet or the control period start (PRE), one week before the competition (MID), after the competition (COMP) and after a recovery period (POST), during which the participants are advised to continue their normal training regimen, but to stop competition dieting. Participants will spend three hours in the laboratory between 0700-1300. The control group will be advised to maintain their normal physical activity diet throughout the study. The participants will be given identification numbers and the research group is blinded so that they do not know which group participants belong to. All measurements will be conducted at the same time (always within max ±1 hour) due to the importance of standardizing the time of the day of measurements.
Study NCT02157610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke \<10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
Study NCT02157610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REDCap
Description: REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
Study NCT02157610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saliva Test
Description: Saliva test performed at 3, 6, 12, and 18 months.
Study NCT02157610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Sessions
Description: 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
Study NCT02157610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
Study NCT01186757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 1.6 mg BID
Study NCT01186757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 4mg BID
Study NCT01186757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03715455
Description: PF-03715455 10 mg BID
Study NCT01186757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03974061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
Study NCT04290585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04290585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive text message reminders
Study NCT03974061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Intervention
Description: The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
Study NCT00652834 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Small bowel capsule endoscopy (SBCE)
Description: SBCE will be performed at Day 2 and Day 30.
Study NCT00652834 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: myfortic
Description: switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
Study NCT04037215 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE
Description: Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~* children controls not achieved with normal BMI;~* children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders.
Study NCT04742023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Application
Description: The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied and values interpreted by nursing.
Study NCT04742023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Finger Stick Glucose Measurement
Description: Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
Study NCT04742023 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Finger Stick Glucose Measurement
Description: Patients post-renal transplant will have finger-stick glucose measurements checked prior to meals.
Study NCT04742023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Insulin will be administered.
Study NCT04742023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin will be administered.
Study NCT04742023 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Glucose Monitor Placebo Applied
Description: The Guardian™ Sensor glucose sensor is part of the Medtronic Continuous Glucose Monitoring (CGM) system. The system then uses these signals to provide sensor glucose values. Patients post-renal transplantation will have CGMs applied however values will not be interpreted.
Study NCT00850330 — intervention group
Intervention type: OTHER
Intervention: on line software to detect DI early on
Description: Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
Study NCT04605250 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory variability before and after surgery
Description: The procedure consist of measuring thoracic chest movement and then calculating the respiratory variability reflected by the coefficient of variation in patients undergoing a surgery. A first recording is done during preoxygenation period using as baseline for further comparisons. (T0, 10 min) The second recording is after extubation during the postoperative recovering period, 30 minutes after interruption of sedations. (T1, 20 min, SSPI ou SIPO) The third recording is before transferring back to classical hospitalization, 1h after T1 (20 min). A fourth recording will be realized 24h after surgery for patients hospitalized in the post operative intensive care unit (T3, 20 min) Optional recordings may be realized if the patient is developing a postoperative respiratory complication during his hospital stay. A follow up for maximum 7 days consisting in consulting the medical file will be realized.
Study NCT03113344 — intervention group
Intervention type: DRUG
Intervention: cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
Study NCT02712203 — intervention group
Intervention type: BIOLOGICAL
Intervention: MMR vaccine / MMRV vaccine
Description: Subcutaneous injection, two doses
Study NCT00553254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
Study NCT01190527 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: FDG-PET
Description: This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
Study NCT01942369 — intervention group
Intervention type: DRUG
Intervention: Triptorelin Acetate 3.75mg intramuscular injection
Description: Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks.
Study NCT03277599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV patient-controlled analgesia (PCA) tramadol
Description: Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
Study NCT03277599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
Study NCT03277599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Great Auricular nerve block
Description: ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
Study NCT04957589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Description: A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day.
Study NCT04957589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Calorie Diet
Description: A dietary intervention consisting of four meals (provided by LighterLife®), totaling approximately 600kcal/day (each meal comprising approximately 150kcal/day). Participants are provided with a choice of one of six meal protocols, which consist of a pre-set combination of meals that arrive at approximately 52g protein, more than 15g fibre and less than 20g sugar per day.
Study NCT04957589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The HIIT training will consist of a five-exercise approach across three movements (star jumps, standing squats, on-the-spot-sprinting, standing squats and star jumps), which are collectively described as a cycle in this context. Each exercise is performed for 60 seconds with a 90 seconds recovery period. Each training session will begin with a two minute warm-up and cooldown (on-the-spot-jogging) followed by five minutes of static stretching. Volunteers would aim to exceed the initial number of star jumps and standing squats in the subsequent attempt per cycle. A total of three training sessions per week are to be completed, preferably non-consecutive but may be consecutive on no more than two training sessions per week. Progression is through a gradual increase in volume (repetitions of star jumps and standing squats) on a per-session basis.
Study NCT04278820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQA3526
Description: Tablet(s) administered orally once daily
Study NCT04278820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match TQA3526
Description: Tablet(s) administered orally once daily
Study NCT01193270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
Study NCT03748550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
Study NCT06637202 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: postoperative radiotherapy
Description: 50 Gy in 25 fractions
Study NCT02957240 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury.